skip to main content

Low-grade Glioma Timing — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardCNS TumoursLow-grade Glioma TimingSCE Medical Oncology

A 40-year-old man with low-grade glioma (IDH-mutant, 1p/19q intact astrocytoma, WHO grade 2) undergoes subtotal resection. Post-operative MRI shows residual tumour. He has no neurological deficits and is neurologically stable. Two management strategies are debated: immediate adjuvant treatment versus watchful waiting with treatment at progression. What does the EORTC 22845 trial inform?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: BThe EORTC 22845 trial showed early RT improved PFS but NOT OS compared with deferred RT at progression

EORTC 22845 randomised patients with low-grade glioma to immediate vs deferred RT. While early RT improved PFS (5.3 vs 3.4 years), there was no OS difference (7.4 vs 7.2 years). This supports watchful waiting with serial MRI in selected patients (young, neurologically intact, maximal resection) to defer RT-associated neurocognitive toxicity. When treatment is indicated (symptoms, growth, transformation), RT + temozolomide (CATNON trial for astrocytomas) or RT + PCV (for oligodendrogliomas) is used.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer